NASDAQ:NBIX

Neurocrine Biosciences - NBIX News Today

$97.05

+1.36 (+1.42%)

(As of 03/24/2023 12:00 AM ET)

Add

Compare

Today's Range: $95.02
▼
$97.48
50-Day Range: $94.11
▼
$111.36
52-Week Range: $75.25
▼
$129.29

Volume: 801,631 shs
Average Volume: 696,269 shs
Market Capitalization: $9.37 billion

P/E Ratio: 63.43
Dividend Yield: N/A
Price Target: $125.65

Institutional Ownership

Get Neurocrine Biosciences News Delivered to You Automatically

NBIX Media Mentions By Week

NBIX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

NBIX
News Sentiment
▼
1.15

0.72
▲
Average
Medical
News Sentiment

NBIX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

NBIX Articles
This Week
▼
8

4
▲
NBIX Articles
Average Week

Source

Source	Headline
	Hennion & Walsh Asset Management Inc. Makes New $544,000 Investment in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) marketbeat.com - March 26 at 4:17 AM
	Congress Asset Management Co. MA Decreases Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) marketbeat.com - March 24 at 11:21 AM
	Tealwood Asset Management Inc. Sells 1,146 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) marketbeat.com - March 23 at 9:51 AM
	Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by Assenagon Asset Management S.A. marketbeat.com - March 22 at 5:28 AM
	DNB Asset Management AS Sells 1,105 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) marketbeat.com - March 21 at 5:53 AM
	Citigroup Sticks to Its Buy Rating for Neurocrine (NBIX) markets.businessinsider.com - March 22 at 9:01 AM
	Neurocrine Biosciences to Present at the Stifel 2023 CNS Days finance.yahoo.com - March 21 at 7:22 PM
	Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives $125.65 Consensus PT from Analysts americanbankingnews.com - March 17 at 3:38 AM
	Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (valbenazine) Capsule Contents via Soft Foods or Feeding Tube at AMDA - PALTC 2023 Annual Conference finance.yahoo.com - March 9 at 9:32 AM
	Neurocrine Biosciences to Participate at Investor Conferences in March finance.yahoo.com - March 8 at 6:30 PM
	‘2023 Rally Was a Bull Trap,’ Says Morgan Stanley. But These Stocks Still Have Upside finance.yahoo.com - March 5 at 11:15 PM
	Evercore ISI Group Upgrades Neurocrine Biosciences (NBIX) msn.com - March 4 at 4:47 PM
	Analyst Expectations for Neurocrine Biosciences's Future markets.businessinsider.com - March 3 at 6:07 PM
	Neurocrine Biosciences Presents Data on Improvements Over Time with Long-Term Use of INGREZZA® (valbenazine) Capsules in Older and Elderly Patients at the American Association for Geriatric Psychiatry 2023 Annual Meeting finance.yahoo.com - March 3 at 6:07 PM
	Neurocrine Biosciences Presents Data on Improvements Over Time with Long-Term Use of INGREZZA Capsules in Older and Elderly Patients investing.com - March 3 at 8:50 AM
	Neurocrine Biosciences Stock (NASDAQ:NBIX), Quotes and News Summary benzinga.com - March 1 at 10:18 PM
	First Week of NBIX April 21st Options Trading nasdaq.com - February 19 at 2:44 PM
	Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides finance.yahoo.com - February 14 at 7:31 PM
	Neurocrine Biosciences Full Year 2022 Earnings: EPS Misses Expectations finance.yahoo.com - February 9 at 10:33 AM
	Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (INCY), Neurocrine (NBIX) and Deciphera Pharmaceuticals (DCPH) markets.businessinsider.com - February 8 at 11:37 PM
	Investors one-year returns in Neurocrine Biosciences (NASDAQ:NBIX) have not grown faster than the company's underlying earnings growth finance.yahoo.com - February 8 at 8:35 AM
	Neurocrine Biosciences to Present at the SVB Securities Global Biopharma Conference finance.yahoo.com - February 7 at 8:04 PM
	Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2022 Earnings Call Transcript finance.yahoo.com - February 7 at 3:04 PM
	Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates finance.yahoo.com - February 6 at 1:38 PM
	Neurocrine Reports 3,000% Profit Growth, But Shares Unexpectedly Tumble finance.yahoo.com - February 6 at 1:38 PM
	If You're in Neurocrine Biosciences Consider Getting Out: Here's Why finance.yahoo.com - February 6 at 1:38 PM
	Neurocrine Biosciences Non-GAAP EPS of $1.24 misses by $0.20, revenue of $412M beats by $3.04M msn.com - February 6 at 8:38 AM
	Ingrezza's Potential To Dominate The Huntington's Chorea Market: A Boost For Neurocrine Investors seekingalpha.com - February 4 at 8:30 AM
	Neurocrine Biosciences Q4 2022 Earnings Preview seekingalpha.com - February 3 at 12:29 PM
	Neurocrine Biosciences Earnings Preview msn.com - February 3 at 12:28 PM
	Catalent (CTLT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release finance.yahoo.com - January 31 at 1:38 PM
	Neurocrine Biosciences: Stencil In These Important Dates seekingalpha.com - January 25 at 5:41 PM
	NBIX Neurocrine Biosciences, Inc. seekingalpha.com - January 24 at 6:21 AM
	Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2022 Financial Results finance.yahoo.com - January 17 at 5:53 PM
	Analysts’ Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE) and Neurocrine (NBIX) markets.businessinsider.com - January 12 at 8:11 AM
	Neurocrine, Voyager To Advance Multiple Gene Therapies For Neurological Diseases Treatment nasdaq.com - January 11 at 9:46 AM
	Voyager Could Get Up to $4.4 Billion in Neurocrine Partnership bloomberg.com - January 9 at 8:25 PM
	Voyager to Get as Much as $1.7 Billion in Neurocrine Partnership bloomberg.com - January 9 at 3:25 PM
	Voyager, Neurocrine sign new deal worth up to $4.2B finance.yahoo.com - January 9 at 3:25 PM
	Voyager jumps 29% on licensing deal with Neurocrine msn.com - January 9 at 10:24 AM
	Dow Jones Rallies On December Jobs Report; Tesla Stock Dives To New Low On China Price Cuts finance.yahoo.com - January 6 at 12:50 PM
	Neurocrine Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference finance.yahoo.com - January 3 at 7:08 PM
	Dow Jones Futures Rise Ahead Of Economic Data; Tesla Stock Set To Rebound Amid Historic Plunge finance.yahoo.com - December 28 at 9:02 AM
	Dow Jones Futures Rise Ahead Of Housing Data; Tesla Plunges On Reduced Production Schedule finance.yahoo.com - December 27 at 8:37 AM
	Dow Jones Futures Reverse Lower On Inflation Data; Tesla Stock Rallies On Elon Musk Comments finance.yahoo.com - December 23 at 8:43 AM
	Neurocrine Biosciences Announces U.S. FDA Accepts Supplemental New Drug Application for Valbenazine as a Treatment for Chorea Associated with Huntington Disease finance.yahoo.com - December 22 at 8:08 PM
	Dow Jones Giant UnitedHealth Among 5 Resilient Stocks In Sickly Market Rally finance.yahoo.com - December 17 at 8:49 AM
	Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum? finance.yahoo.com - December 10 at 9:10 AM
	Mizuho Securities Keeps Their Hold Rating on Neurocrine (NBIX) markets.businessinsider.com - December 7 at 2:04 AM
	Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-827104 in Pediatric Patients with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep finance.yahoo.com - December 6 at 9:03 PM
	Neurocrine Biosciences Presents Demographic and Clinical Characteristics Data of Pediatric Patients with SCN8A-Related Epilepsies at AES 2022 finance.yahoo.com - December 2 at 9:48 AM
	Hot Biotech Stocks Rise Into Leadership; Pass Buy Points Or Build Bases finance.yahoo.com - November 25 at 4:44 PM
	Why The Market Rally Could Use A Holiday; Tesla Rebounds, 5 Stocks Near Buy Points finance.yahoo.com - November 24 at 5:17 AM
	Neurocrine Biosciences downgraded to in line from outperform at Evercore ISI marketwatch.com - November 14 at 6:32 AM
	Could Pfizer Stock Help You Retire a Millionaire? stocknews.com - November 11 at 9:28 AM

Get Neurocrine Biosciences News Delivered to You Automatically

This page (NASDAQ:NBIX) was last updated on 3/26/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Neurocrine Biosciences - NBIX News Today

NBIX Media Mentions By Week

NBIX Media Sentiment

NBIX News Coverage

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info